|Day Low/High||82.44 / 83.27|
|52 Wk Low/High||69.89 / 104.75|
Shares of the global healthcare company, Novartis, are down after it saw its profits fall in the second quarter.
Novartis (NVS) stock is lower in pre-market trading on Tuesday after cautioning that full-year profit could slide on more investments in its heart-failure drug.
A closely watched market sentiment indicator points to gloom in Germany and the euro area, while U.K. price growth picks up pace.
The pharmaceuticals company, led by CEO Joe Jiminez, had its first full quarter of generic competition for its Gleevec cancer drug.
TheStreet highlights 3 stocks pushing the drugs industry lower today.
At least one company follower believes the divestiture of Shire's Neurology division for as much as $13 billion would be a logical next move.
You have to be impressed by the breadth of XNCR's pipeline and significant partnerships with major players.
Juno Therapeutics reminds investors yet again that the business of biotech -- developing new medicines that are effective and reasonably safe -- is hard to get right.
Here's a technical look at how to trade some of the biggest stocks on the market right now.
Cramer says Wynn is fantastic but he's avoiding Valeant.
When short-sellers get caught leaning the wrong way, that's a recipe for explosive moves to the upside, Cramer says.
Here are Wednesday's top research calls, including downgrades for Comerica, Coach and Harman, and an upgrade for Oracle.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: APLP, DCI, DWRE, ISIL, MBT, NVS, STC Downgrades: AMG, COH, EQS, GIG, LECO, MITK, NEWM, TRNC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Trade-Ideas LLC identified Novartis (NVS) as a pre-market leader candidate
Stay away from banks, but pharmaceuticals and tech stocks look good, analysts say.
It was all about the green at this week's Cannabis World Congress in New York.
The rally has been strong and the bull market is taking a deserved rest, Cramer says.
TheStreet highlights 3 stocks pushing the health care sector lower today.
Here's the lowdown on the biotech companies that have come public this year.
Novartis has had to cope with the expiration of some patents, but it should benefit from its varied products and significant investment in research and development.
Problems with mesh products and high leverage might scare away a potential buyer.
Shares of Valeant Pharmaceuticals jumped following last night's report by The Wall Street Journal saying that the company rejected a joint takeover approach from Takeda Pharmaceuticals and TGP Capital.
Trade-Ideas LLC identified Novartis (NVS) as a pre-market mover with heavy volume candidate
Ziopharm is its own mini biotech bubble, held aloft unjustifiably because of its interlocking relationship with Intrexon, the synthetic biology company majority-owned by R.J. Kirk.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
AstraZeneca, Bayer, Eli Lilly and Merck are just a few of the names that may join a bidding war for the cancer drug maker, analysts say.
New Chairman and CEO Joe Papa can't stop the world from gunning for Valeant.